Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Target Price at $14.57

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been assigned a consensus rating of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $14.57.

AMLX has been the topic of a number of recent analyst reports. The Goldman Sachs Group boosted their price target on shares of Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Friday, July 12th. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Amylyx Pharmaceuticals in a report on Friday, October 18th. Bank of America upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the company from $4.20 to $10.00 in a report on Wednesday, October 23rd. Finally, Leerink Partners set a $4.00 price objective on shares of Amylyx Pharmaceuticals and gave the company a “market perform” rating in a research note on Friday, October 18th.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $6.54 on Friday. Amylyx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $19.95. The company’s 50 day simple moving average is $3.58 and its 200-day simple moving average is $2.49. The firm has a market capitalization of $445.26 million, a P/E ratio of -2.67 and a beta of -0.70.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.35). Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. The firm had revenue of ($1.02) million for the quarter, compared to analyst estimates of $18.83 million. During the same quarter in the prior year, the firm earned $0.31 EPS. Sell-side analysts predict that Amylyx Pharmaceuticals will post -3.03 EPS for the current fiscal year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 11,442 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $36,614.40. Following the transaction, the insider now owns 143,801 shares in the company, valued at approximately $460,163.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 18,589 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $3.20, for a total value of $59,484.80. Following the completion of the sale, the chief executive officer now directly owns 3,120,569 shares of the company’s stock, valued at $9,985,820.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Camille L. Bedrosian sold 11,442 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $3.20, for a total transaction of $36,614.40. Following the completion of the sale, the insider now directly owns 143,801 shares of the company’s stock, valued at $460,163.20. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.70% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. grew its position in Amylyx Pharmaceuticals by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock worth $42,000 after acquiring an additional 5,104 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 52,575.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock worth $43,000 after buying an additional 15,247 shares during the period. Algert Global LLC bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $47,000. CWM LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 104.2% during the 2nd quarter. CWM LLC now owns 28,643 shares of the company’s stock worth $54,000 after buying an additional 14,613 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 113.6% during the 2nd quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock worth $106,000 after buying an additional 29,697 shares during the period. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.